10X Genomics Inc vs Zillow Group Inc Class A — how do they compare? 10X Genomics Inc trades at $57.7 (market cap $7.61B), while Zillow Group Inc Class A trades at $34.4 (market cap $7.68B). The key difference: 10X Genomics Inc and Zillow Group Inc Class A are close in size by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals.
| TXG | ZG | |
|---|---|---|
Market Cap | $7.61B | $7.68B |
Sector | Health | Media |
52-Week High | $58.57 | $86.76 |
52-Week Low | $11.34 | $29.14 |
Enterprise Value | $7.14B | $7.56B |
Signals from Pluang's Aura AI — not financial advice
TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.
Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.
Zillow Group (ZG) trades at $33.46, down 1.81% with a bearish technical signal. The company shows improving fundamentals with Q2 2026 earnings beats and 18% revenue growth, though net margins remain thin at 1.96%. Recent news highlights strong performance in the preferred agent model but is overshadowed by multiple securities class action lawsuits with August 2026 deadlines. Valuation metrics appear elevated with a P/E of 149, while analyst consensus targets $47.56 with mixed ratings.
The outlook is cautiously optimistic given ZG's business model transition and revenue growth, but significant legal overhangs and high valuation create near-term risks. Long-term potential exists if monetization improvements continue, though investors should weigh legal uncertainties against fundamental progress.
Trailing returns across standard periods
Latest headlines on both assets
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →